Valued at $576.3M at its Series B, Sep 2026. Nothing has traded since.
- ·The post-money valuation on its round
- ·The complete investor list: 12 names
- ·Watch Superluminal Medicines: the Monday email on marks, rounds and moves
Valuation timeline
1 priced round · 32 daily marks since · Sep 2026 – Oct 2026Membership and data by Private Market View
Superluminal Medicines funding history
4 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Sep 2026 | Series B | $65.5M | ▮ | ▮ |
| Aug 2025 | Debt | $5.0M | ▮ | ▮ |
| Jan 2025 | Early Stage VC (Series A) | $120.0M | ▮ | ▮ |
| Aug 2023 | Seed Round | $32.7M | ▮ | ▮ |
Membership and data by Private Market View
Superluminal Medicines valuation
Superluminal Medicines was valued at $576 million at its Series B in Sep 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
Recent activity
In the last 90 days, Superluminal Medicines's record added 1 funding round.
How much has Superluminal Medicines raised?
Superluminal Medicines has raised $158 million across 4 recorded rounds since 2023. The largest was a $65.5 million Series B in Sep 2026. 1 of the rounds disclosed a post-money valuation.
Superluminal Medicines has filed 3 Form Ds with the SEC since 2023, most recently in Aug 2025 ($5 million sold to 1 investor).
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: VeraDermics (NYS: MANE) ($596 million), Strand Therapeutics ($571 million) and Bambusa Therapeutics ($555 million).
How Superluminal Medicines's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Superluminal Medicines, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →
Frequently asked about Superluminal Medicines
- What is Superluminal Medicines worth?
- Superluminal Medicines is valued at $576.3M as of Oct 2026. Valued at $576.3M at its Series B, Sep 2026. Nothing has traded since.
- How much has Superluminal Medicines raised?
- Superluminal Medicines has raised $157.7M in total funding across 4 recorded rounds.
- When did Superluminal Medicines last raise?
- Superluminal Medicines last raised in Sep 2026 (Series B), raising $65.5M.